Product Dossier
AQUIPTA
Product Dossier for AQUIPTA (atogepant, AbbVie). ARTG record, PBS listing, PBAC outcomes, AusPAR — compiled by arcimedes.
- Sponsor: AbbVie
- Active ingredient: atogepant
- Therapeutic area: Neurology
- Same area: GILENYA
- Same area: RIVOTRIL
What it is
AQUIPTA is atogepant, available in 10 mg, 30 mg and 60 mg tablet strengths.
Approved indications
— Prophylaxis of migraine in adults who have at least four migraine days per month.
Dosing overview
No dosing information is available in the provided sources.
Key safety warnings
No safety warnings information is available in the provided sources.
Contraindications
No contraindications information is available in the provided sources.
PBS listing
No PBS listing information is available in the provided sources.
Regulatory history
AQUIPTA was approved by the TGA on 14 November 2023 for the prophylaxis of migraine in adults who experience at least four migraine days per month. The medicine was first listed on the ARTG on 12 December 2023 in all three strengths. The PBAC considered the indication of prophylaxis of migraine in July 2023 and did not recommend it.